MiR-19b regulates hTERT mRNA expression through targeting PITX1 mRNA in melanoma cells

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Ohira, Takahito ^a   Naohiro, Sunamura ^a   Nakayama, Yuji ^b   Osaki, Mitsuhiko ^b,c   Okada, Futoshi ^b,c   Oshimura, Mitsuo ^b   Kugoh, Hiroyuki ^a,b  

^a TOTTORI UNIVERSITY   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

^c TOTTORI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3' UNTRANSLATED REGION; ANTISENSE OLIGONUCLEOTIDE; HOMEOBOX PROTEIN PITX1; MESSENGER RNA; MICRORNA; MIRN19 MICRORNA, HUMAN; PAIRED BOX TRANSCRIPTION FACTOR; TELOMERASE; TERT PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CHEMISTRY; DOWN REGULATION; GENETICS; HEK293 CELL LINE; HUMAN; MELANOMA; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROTEIN SYNTHESIS; SEQUENCE ALIGNMENT; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; ANIMALS; BASE SEQUENCE; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; HEK293 CELLS; HUMANS; MELANOMA; MICRORNAS; OLIGONUCLEOTIDES, ANTISENSE; PAIRED BOX TRANSCRIPTION FACTORS; PROTEIN BIOSYNTHESIS; RNA, MESSENGER; SEQUENCE ALIGNMENT; TELOMERASE;

EID: 84944098807     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep08201     Document Type: Article

References (48)

1. Bernardes de Jesus, B.&Blasco, M. A. Telomerase at the intersection of cancer and aging. Trends Genet 29, 513-520 (2013).
2. Hoffmeyer, K. et al. Wnt/b-catenin signaling regulates telomerase in stem cells and cancer cells. Science 336, 1549-1554 (2012).
3. Ghosh, A. et al. Telomerase directly regulates NF-kB-dependent transcription. Nat Cell Biol 14, 1270-1281 (2012).
4. Qi, D. L. et al. Identification of PITX1 as a TERT suppressor gene located on human chromosome 5. Mol Cell Biol 31, 1624-1636 (2011).
5. Kolfschoten, I. G. et al. A genetic screen identifies PITX1 as a suppressor of RAS activity and tumorigenicity. Cell 121, 849-858 (2005).
6. Chen, Y. et al. Decreased PITX1 homeobox gene expression in human lung cancer. Lung Cancer 55, 287-294 (2007).
7. Chen, Y. N., Chen, H., Xu, Y., Zhang, X. & Luo, Y. Expression of pituitary homeobox 1 gene in human gastric carcinogenesis and its clinicopathological significance. World J Gastroenterol 14, 292-297 (2008).
8. Lord, R. V. et al. Increased CDX2 and decreased PITX1 homeobox gene expression in Barrett's esophagus and Barrett's-associated adenocarcinoma. Surgery 138, 924-931 (2005).
9. Nakabayashi, M. et al. PITX1 is a reliable biomarker for predicting prognosis in patients with oral epithelial dysplasia. Oncol Lett 7, 750-754 (2014).
10. Osaki, M. et al. Decreased PITX1 gene expression in human cutaneousmalignant melanoma and its clinicopathological significance. Eur J Dermatol 23, 344-349 (2013).
11. Iorio, M. V. & Croce, C. M. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 4, 143-159 (2012).
12. Medina, P. P., Nolde, M. & Slack, F. J. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature 467, 86-90 (2010).
13. Song, S. J. et al. MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling. Cell 154, 311-324 (2013).
14. Valeri, N. et al. MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer. Cancer Cell 25, 469-483 (2014).
15. Zhu, H. Y. et al. MicroRNA-21 regulates hTERT via PTEN in hypertrophic scar fibroblasts. PLoS One 9, e97114 (2014).
16. Olive, V., Jiang, I. & He, L. mir-17-92, a cluster of miRNAs in the midst of the cancer network. Int J Biochem Cell Biol 42, 1348-1354 (2010).
17. Landais, S., Landry, S., Legault, P. & Rassart, E. Oncogenic potential of the miR-106-363 cluster and its implication in human T-cell leukemia. Cancer Res 67, 5699-5707 (2007).
18. Olive, V. et al. miR-19 is a key oncogenic component ofmir-17-92. Genes Dev 23, 2839-2849 (2009).
19. Mavrakis, K. J. et al. Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia. Nat Cell Biol 12, 372-379 (2010).
20. Liang, Z., Li, Y., Huang, K.,Wagar, N. & Shim, H. Regulation of miR-19 to breast cancer chemoresistance through targeting PTEN. Pharm Res 28, 3091-3100 (2011).
21. Martín-Rivera, L., Herrera, E., Albar, J. P. & Blasco, M. A. Expression of mouse telomerase catalytic subunit in embryos and adult tissues. Proc Natl Acad Sci USA 95, 10471-10476 (1998).
22. Daniel, M., Peek, G. W. & Tollefsbol, T. O. Regulation of the human catalytic subunit of telomerase (hTERT). Gene 498, 135-146 (2012).
23. Qian, Y., Yang, L. & Cao, S. Telomeres and telomerase in T cells of tumor immunity. Cell Immunol 289, 63-69 (2014).
24. Vanhaesebroeck, B., Stephens, L. & Hawkins, P. PI3K signalling: the path to discovery and understanding. Nat Rev Mol Cell Biol 13, 195-203 (2012).
25. Zhou, C., Bae-Jump, V. L., Whang, Y. E., Gehrig, P. A. & Boggess, J. F. The PTEN tumor suppressor inhibits telomerase activity in endometrial cancer cells by decreasing hTERT mRNA levels. Gynecol Oncol 101, 305-310 (2006).
26. Sharma, G. G. et al. hTERT associates with human telomeres and enhances genomic stability and DNA repair. Oncogene 22, 131-146 (2003).
27. Ota, A. et al. Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res 64, 3087-3095 (2004).
28. Volinia, S. et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 103, 2257-2261 (2006).
29. Petrocca, F., Vecchione, A. & Croce, C. M. Emerging role of miR-106b-25/miR-17-92 clusters in the control of transforming growth factor beta signaling. Cancer Res 68, 8191-8194 (2008).
30. He, L. et al. A microRNA polycistron as a potential human oncogene. Nature 435, 828-833 (2005).
31. Landais, S., Landry, S., Legault, P. & Rassart, E. Oncogenic potential of the miR-106-363 cluster and its implication in human T-cell leukemia. Cancer Res 67, 5699-5707 (2007).
32. Hoeflich, K. P. et al. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signalregulated kinase/mitogen-activated protein kinase pathway suppression. Cancer Res 69, 3042-3051 (2009).
33. He, L. et al. A microRNA polycistron as a potential human oncogene. Nature 435, 828-833(2005).
34. Mu, P. et al. Genetic dissection of the miR-17,92 cluster of microRNAs in Mycinduced B-cell lymphomas. Gnes Dev 23, 2806-2811 (2009).
35. Lu, Y., Thomson, J.M., Wong, H. Y., Hammond, S. M. & Hogan, B. L. Transgenic over-expression of the microRNA miR-17-92 cluster promotes proliferation and inhibits differentiation of lung epithelial progenitor cells. Dev Biol 310, 442-453 (2007).
36. Wu, C. et al. Serum levels of miR-19b and miR-146a as prognostic biomarkers for non-small cell lung cancer. Tohoku J Exp Med 232, 85-95 (2014).
37. Gantier, M. P. et al. A miR-19 regulon that controls NF-kB signaling. Nucleic Acids Res 40, 8048-8058 (2012).
38. Jang, S. & Atkins, M. B. Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies. Clin Pharmacol Ther 95, 24-31 (2014).
39. Fuziwara, C. S. & Kimura, E. T. High iodine blocks a Notch/miR-19 loop activated by the BRAF(V600E) oncoprotein and restores the response to TGFb in thyroid follicular cells. Thyroid 24, 453-462 (2014).
40. Sasaki, Y. et al. BRAF point mutations in primary melanoma show different prevalences by subtype. J Invest Dermatol 123, 177-183 (2004).
41. Kurokawa, K. et al. Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells. J Gastroenterol 47, 883-895 (2012).
42. Wu, C. et al. Serum levels of miR-19b and miR-146a as prognostic biomarkers for non-small cell lung cancer. Tohoku J Exp Med 232, 85-95 (2014).
43. Wu, Q. et al. MiR-19b/20a/92a regulates the self-renewal and proliferation of gastric cancer stem cells. J Cell Sci 126, 4220-4229 (2013).
44. Chen, D. et al. BRAF mutations in patients with non-small cell lung cancer: a systematic review and meta-analysis. PLoS One 9, e101354 (2014).
45. Elisei, R. et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab 93, 3943-3949 (2008).
46. Li, W. Q. et al. BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status. Mol Cancer 5, 2 (2006).
47. Maldonado, J. L. et al. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 95, 1878-1890 (2003).
48. Uno, N. et al. The transfer of human artificial chromosomes via cryopreserved microcells. Cytotechnology 65, 803-809 (2013).